Breaks Categories: News

TuesdayMay 05, 2026 9:50 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Initiates First Commercial Manufacturing Order For Preservative-Free Ketamine

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has initiated its first commercial manufacturing order of preservative-free ketamine in anticipation of potential approval under the Generic Drug User Fee Act in summer 2026, supported by stability data from multiple registration batches and a successful third-party manufacturing audit. To view the full press release, visit https://ibn.fm/yEXl3 About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone).…

Continue Reading

MondayMay 04, 2026 10:55 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures $22.5 Million Private Placement Financing

CNS Pharmaceuticals (NASDAQ: CNSP) announced it has entered into securities purchase agreements for a private placement expected to generate approximately $22.5 million in gross proceeds, with participation from institutional healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners. The company said proceeds will support its strategy to acquire and advance new assets, along with working capital and general corporate purposes, while A.G.P./Alliance Global Partners acted as the sole placement agent for the transaction. To view the full press release, visit https://ibn.fm/usrIh About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies…

Continue Reading

MondayMay 04, 2026 9:30 am

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Launches Redesigned Platform and Multi-Site Digital Ecosystem

HealthLynked (OTCQB: HLYK) announced the launch of a redesigned consumer platform and multi-site digital ecosystem aimed at improving healthcare access, reducing inefficiencies and enhancing engagement across patients, providers, partners and investors. The company said the new architecture includes dedicated platforms for consumer access, provider engagement, business partnerships and investor relations, supporting its strategy to build a scalable, consumer-driven healthcare platform with national reach and future AI-driven capabilities. To view the full press release, visit https://ibn.fm/cJfsm About HealthLynked Corp. HealthLynked Corp. enhances healthcare through personalized care management that improves outcomes and reduces costs. Its cloud-based platform connects patients with providers for…

Continue Reading

ThursdayApr 30, 2026 9:50 am

BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Receives FDA IND Clearance for Telomir-Zn in Triple-Negative Breast Cancer

Telomir Pharmaceuticals (NASDAQ: TELO), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for Telomir-Zn to treat advanced or metastatic triple-negative breast cancer. The clearance enables initiation of a first-in-human Phase 1/2 clinical trial designed to evaluate safety, dosing and preliminary antitumor activity, supported by preclinical pharmacology, toxicology and biomarker data as the Company advances its lead candidate toward clinical development. To view the full press release, visit https://ibn.fm/p4e9J About Telomir Pharmaceuticals Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and…

Continue Reading

ThursdayApr 30, 2026 9:30 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances AI and Robotics Platform Toward Initial Commercial Deployment

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biotechnology company, reported continued progress on its proprietary AI platform and robotics integration as it nears initial commercial deployment. The Company has integrated approximately 28 million scientific abstracts into its PDAOAI platform and combined it with robotics developed alongside TechForce Robotics, enabling real-time, automated workflows designed to improve efficiency and support compliance in pharmaceutical development and manufacturing. To view the full press release, visit https://ibn.fm/2uitp About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and…

Continue Reading

ThursdayApr 30, 2026 9:20 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q1 2026 Earnings Call and Provide Strategic Updates

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter results ended March 31, 2026, and provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection and AI programs. To view the full press release, visit https://ibn.fm/yN939 About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting…

Continue Reading

WednesdayApr 29, 2026 10:20 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Files Patent Applications for AI Voice Intoxication Detection Technology

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), a biotechnology company commercializing AI-driven voice technology for drug and alcohol intoxication detection, announced it has filed patent applications for its technology that uses voice and artificial intelligence (“AI”) to detect intoxication. The company said its Edge AI Intoxication Detection Kiosks use more than 50 million data points to predict drug and alcohol intoxication by analyzing the human voice, with commercial testing hardware and software solutions for the mining and aviation industries on track for delivery…

Continue Reading

TuesdayApr 28, 2026 11:54 am

BioMedNewsBreaks — ARMR Sciences Inc. Advances Fentanyl Vaccine with Private Placement Led by Joseph Gunnar & Co.

ARMR Sciences completed a private placement financing with strategic and institutional investors, with Joseph Gunnar & Co., LLC acting as placement agent, as the company advances toward human trials for its fentanyl vaccine. Backed by the U.S. Department of War, the vaccine is designed to prevent fatal overdoses and address threats from substances such as fentanyl, supporting continued development and clinical progression. To view the announcement, visit https://ibn.fm/t39w2 About ARMR Sciences Inc. ARMR Sciences Inc. is America's biodefense technology company, developing next-generation countermeasures against synthetic drug threats, such as fentanyl. Through its foundational license, ARMR is backed by early-stage research funding from the…

Continue Reading

MondayApr 27, 2026 9:00 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Regains Compliance With Nasdaq Minimum Bid Price Requirement

NextPlat (NASDAQ: NXPL, NXPLW) announced it has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) following receipt of a compliance letter from The Nasdaq Stock Market LLC on April 27, 2026. Nasdaq determined the Company’s shares maintained a closing bid price of at least $1.00 for 10 consecutive business days from April 13, 2026 to April 24, 2026, and confirmed the matter is now closed, with NextPlat continuing to trade on The Nasdaq Capital Market under the ticker NXPL. To view the full press release, visit: https://ibn.fm/RUz3J About NextPlat Corp. NextPlat is a global…

Continue Reading

FridayApr 24, 2026 11:02 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Editorial on Pipeline-Driven Valuation 

Oncotelic Therapeutics (OTCQB: OTLC) is featured in a NetworkNewsAudio Audio Press Release titled “When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech,” which highlights how late-stage drug development assets increasingly drive valuation in the biopharma sector. The editorial, supported by analysis from McKinsey & Company, notes that companies tend to realize the majority of value creation as products approach commercialization, reflecting reduced risk and clearer revenue visibility, a trend directly relevant to Oncotelic’s oncology-focused pipeline and strategic development approach. To view the full press release, visit https://ibn.fm/0uj56 About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy…

Continue Reading